Further, we constructed a herb-compound-target network that identified HMGCR, MAPK1, and SREBP-2 as targets with high degree values that may be relevant in the context of ZXD-mediated NAFLD treatment. Here, SREBF2 is linked to metabolic dysfunction-associated steatotic liver disease.